论文部分内容阅读
目的:观察临床治疗获益的晚期非小细胞肺癌患者进行自体DC-CIK维持治疗前后生活质量的变化情况。方法:选择规范综合治疗后获益的Ⅲb期或Ⅳ期非小细胞肺癌患者,分为A、B两组,每组25例。A组给予自体DC-CIK维持治疗1个疗程,B组予中成免疫药物(康艾注射液)治疗10天。采用QLICP-LU量表测定患者在入组时、入组后2月的生活质量。统计治疗前后患者的生活质量评分,并分析影响自体DC-CIK治疗效果的因素,观察治疗的安全性。结果:自体DC-CIK维持治疗后患者的生活质量在躯体功能、癌症共性症状和副作用以及肺癌特异性症状等方面较康艾针治疗后的患者有所改善(P<0.05);通过亚组分析得出,自体DC-CIK维持治疗对鳞癌、IV期、年龄大于60岁的男性肺癌患者的生活质量改善较为明显。维持治疗期间未出现严重的骨髓抑制、肝肾毒性及消化道反应,总不良反应发生率4%。结论:自体DC-CIK作为60岁以上临床治疗获益的IV期肺鳞癌男性患者的维持治疗手段,能通过对躯体功能、癌症共性症状和副作用以及肺癌特异性症状等方面的改善,提高患者生活质量,且毒副反应能耐受。
OBJECTIVE: To observe the changes of quality of life before and after autologous DC-CIK maintenance therapy in patients with advanced non-small cell lung cancer who benefit from clinical treatment. Methods: Patients with stage Ⅲb or Ⅳ non-small cell lung cancer that benefited from the comprehensive treatment were selected and divided into A and B groups, with 25 cases in each group. A group given autologous DC-CIK maintenance treatment for a course of treatment, B group to immunization drugs (Kang Ai injection) for 10 days. The QLICP-LU scale was used to measure the quality of life at 2 months after enrollment when patients were enrolled. The quality of life of patients before and after treatment was scored and the factors affecting the effect of autologous DC-CIK treatment were analyzed. The safety of treatment was observed. Results: The quality of life of the patients after autologous DC-CIK maintenance therapy was improved (P <0.05) compared with that of Kangyi acupuncture after physical therapy, symptoms and side effects of cancer and specific symptoms of lung cancer. By subgroup analysis Concluded that maintenance of autologous DC-CIK in squamous cell carcinoma, IV, more than 60 years old male patients with lung cancer better quality of life improved significantly. Maintain the treatment period did not appear serious myelosuppression, liver and kidney toxicity and gastrointestinal reactions, the total incidence of adverse reactions 4%. CONCLUSIONS: Maintenance of autologous DC-CIK as a maintenance treatment for stage IV squamous cell carcinoma of the lung in patients over 60 years of age has been shown to improve patients’ performance through improvements in physical function, common symptoms and side effects of cancer, and lung cancer-specific symptoms Quality of life, and toxic side effects can tolerate.